Cellular Program Behind Aging May Also Shape Embryos, CHARGE Syndrome Review Suggests

Cellular senescence has long been framed as a hallmark of growing old: the irreversible arrest of dividing cells that accumulates in aging tissues, drives chronic inflammation and suppresses tumors. But a new review published in the journal Aging on September 8, 2026, argues that the same cellular program, when it appears temporarily in embryos, may be one of the unsung architects of human development—and that its misregulation could help explain the birth defects seen in CHARGE syndrome, a rare and complex congenital disorder. The review, led by co-first authors Álvaro J. Arana of the Universidad de Santiago de Compostela and Pablo Palau-Irisarri of the Universidad Autónoma de Madrid, with Arana serving as corresponding author, does not claim to have solved the puzzle of CHARGE syndrome. Instead, it assembles anatomical, developmental and molecular evidence into a testable framework, proposing that disruption of developmental senescence deserves a place among the candidate mechanisms behind the disorder.

Developmental senescence differs fundamentally from the senescence associated with aging and disease. During embryogenesis, selected cells enter a transient growth-arrested state in restricted tissues at precise developmental stages. Far from being a pathological accident, this programmed arrest appears to serve constructive purposes: senescent cells secrete signaling molecules that influence neighboring tissue, help remodel embryonic structures and are then cleared, often by the embryonic immune system, once their job is done. In this sense, developmental senescence behaves like a morphogenetic regulator—a temporary scaffold that helps shape organs before being dismantled. The authors of the review capture this idea in a central formulation: developmental senescence acts as a morphogenetic regulator whose activity must be tightly integrated with proliferative cues, differentiation programs and tissue-specific signaling networks.

That integration requirement is precisely where things could go wrong. Because the program must operate at the right place, at the right time and at the right intensity, the reviewers reason that any deviation—excessive senescence, insufficient senescence, senescence that lingers too long, or senescence appearing in the wrong tissue—could interfere with normal morphogenesis. A cellular program designed to sculpt tissue could, if misregulated, deform it. This logic transforms developmental senescence from a curiosity of embryology into a plausible contributor to congenital malformations, and it sets the stage for the review’s central proposal: that CHARGE syndrome, with its distinctive constellation of developmental defects, offers an unusually good model in which to investigate that possibility.

CHARGE syndrome is a rare developmental disorder whose name summarizes its most characteristic features: coloboma of the eye, heart defects, choanal atresia (blockage of the nasal passages), growth and developmental delay, genitourinary abnormalities and characteristic ear defects. The clinical picture varies widely between patients, but the underlying genetics is comparatively straightforward. Most individuals with CHARGE syndrome carry pathogenic variants in a single gene, CHD7, which encodes an ATP-dependent chromatin remodeler—a molecular machine that uses the energy of ATP to restructure how DNA is packaged and, in doing so, regulates which genes are accessible for transcription. Chromatin remodelers sit near the top of gene-regulatory hierarchies, which helps explain why mutations in CHD7 can produce effects across so many organ systems at once.

The first pillar of the review’s argument is anatomical. The authors identify a striking three-way overlap between the tissues affected in CHARGE syndrome, the regions where CHD7 is expressed during embryonic development, and the areas where developmental senescence has been observed in experimental studies. This overlapping map includes structures associated with the eye, the inner ear, the pharyngeal regions and the nervous system—the very systems most commonly disturbed in CHARGE patients. The authors are careful to note that such spatial coincidence does not establish causality. Tissues can overlap for many reasons that have nothing to do with a shared mechanism. But the overlap provides something a hypothesis needs before it can be tested: a defined set of tissues in which to look for a functional connection between CHD7 deficiency and altered senescence.

The inner ear supplies the most compelling example in the review. Developmental senescence is known to contribute to the remodeling of the developing inner ear, a structure whose intricate geometry depends on precisely coordinated tissue sculpting. CHARGE syndrome, meanwhile, frequently involves hypoplasia or complete absence of the semicircular canals, the fluid-filled loops of the inner ear that detect rotational movement and are essential for balance. In mouse models, deficiency of Chd7—the mouse counterpart of the human gene—produces major vestibular abnormalities. Putting these observations together, the authors propose that altered senescence-related remodeling could contribute to the characteristic inner-ear defects associated with CHD7 deficiency. If the cellular program that normally refines inner-ear architecture is mis-timed or mis-located in the absence of functional CHD7, the resulting structure could be underdeveloped or absent.

The second pillar is molecular. CHD7 is not an isolated actor; the review documents its intersection with well-known pathways of cell-cycle arrest and senescence, including the p53 and p21 pathways and TGFβ-related signaling. These pathways form the canonical machinery that cells use to halt division and enter a senescent state. The experimental evidence connecting them to CHD7 is particularly intriguing. In zebrafish embryos, reduced chd7 expression causes cell-cycle arrest alongside increased expression of several cell-cycle inhibitors—the molecular fingerprint of cells being pushed toward arrest. In mouse models, inappropriate activation of p53 can produce major CHARGE-like abnormalities on its own, and, more strikingly, partially reducing the dose of Trp53, the gene encoding p53, can rescue several of the developmental defects caused by Chd7 deficiency. That rescue experiment suggests the two pathways are not merely parallel but functionally entangled: dialing down one can compensate for the loss of the other.

Evidence from other developmental models reinforces the broader principle that senescence must be precisely controlled during embryogenesis. Abnormal senescence has been implicated experimentally in models involving Six1 deficiency, exposure to the drug valproic acid, maternal diabetes and trisomy 21. In each of these contexts, developmental abnormalities appear to arise when senescence occurs in the wrong location, at the wrong time or at an inappropriate level. The review extends this logic to a wider set of congenital conditions, considering whether senescence-related mechanisms might contribute to Rett syndrome, Treacher-Collins syndrome, 22q11.2 deletion syndrome, Waardenburg syndrome and related SOX10-associated disorders, and Kallmann syndrome. Here the authors urge restraint: the evidence varies considerably among these disorders, and it remains unresolved whether the cellular changes observed in them represent authentic developmental senescence or related but distinct cell-arrest states.

The authors themselves are explicit that the connection between CHD7 and developmental senescence remains a working hypothesis. As they state, the available anatomical, developmental and molecular evidence does not yet demonstrate that CHARGE syndrome is a disorder of senescence misregulation. The evidence is heterogeneous and often indirect, assembled from different organisms, different tissues and different experimental systems. What is needed now are direct experiments: mapping senescence markers across CHD7-sensitive embryonic tissues to see whether the spatial and temporal patterns of senescence are actually disturbed when CHD7 is lost, and determining how CHD7 affects chromatin accessibility, cell-cycle control and senescence-associated signaling at the molecular level. Chromatin profiling of CHD7-deficient embryonic cells, combined with single-cell analysis of senescence markers, could reveal whether the chromatin remodeler directly regulates the genetic programs that initiate or maintain developmental senescence.

There is also a therapeutic dimension, approached with appropriate caution. Senescence-modulating approaches—drugs that clear senescent cells or suppress their secretory activity—have shown benefits in some experimental models of developmental defects. But the authors emphasize that developmental senescence is itself a normal and beneficial component of morphogenesis. Bluntly suppressing it during embryogenesis could cause as much harm as the misregulation it aims to correct. Any future intervention would need to be exquisitely targeted in time, tissue and mechanism. For now, the value of the review lies in its framing: it presents CHARGE syndrome as a candidate model for understanding how the misregulation of a normally constructive developmental program could contribute to congenital disease, linking CHD7-dependent chromatin regulation to senescence pathways and embryonic tissue remodeling. Establishing a causal role will require direct functional evidence, particularly in the CHD7-sensitive structures such as the inner ear where the anatomical, developmental and molecular threads of the hypothesis converge most tightly. If those experiments succeed, they would not only illuminate a rare syndrome but also deepen understanding of how embryos use a program usually associated with aging to build new bodies.

Subject of Research: The role of developmental senescence misregulation as a candidate mechanism in CHARGE syndrome

Article Title: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome

Article References: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: developmental senescence, CHARGE syndrome, CHD7, chromatin remodeling, morphogenesis, p53, p21, TGFβ signaling, inner ear, congenital disorders, cell-cycle arrest, embryonic development